Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2010-09-22 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB SCIENCE : Authorisation has been granted for the initiation of four phase 3 studies
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science dated September 22, 2010, announcing that regulatory approvals (IND authorizations from the FDA and positive scientific advice from EMA/Afssaps) have been granted to initiate four Phase 3 clinical studies for their compound masitinib in multiple myeloma, rheumatoid arthritis, asthma, and multiple sclerosis. This content details clinical trial progress, study designs, patient populations, and market positioning, which is characteristic of an update on drug development and clinical pipeline status. This type of announcement, focusing on regulatory milestones and clinical trial progression rather than full financial results (ER/IR) or management changes (MANG), fits best under a general 'Regulatory Filings' or 'Investor Presentation' category. Given the detailed nature of the clinical trial updates and positioning, it is a significant communication aimed at investors regarding R&D progress. Since there is no specific code for 'Clinical Trial Update' or 'R&D Progress', and it is not a formal financial report (10-K, IR, ER), the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general announcement of a significant regulatory/clinical milestone, or potentially 'Investor Presentation' (IP) if viewed as a strategic update, but RNS is safer for regulatory milestones. However, looking closely at the definitions, this is a detailed announcement about the company's pipeline progress, which often accompanies or substitutes for an Investor Presentation (IP) or is a specific type of regulatory announcement. Since it is a detailed announcement about the *initiation* of studies based on regulatory authorization, it is a key piece of investor information. Given the depth of the scientific and market analysis provided, 'Investor Presentation' (IP) is a strong candidate, but 'Regulatory Filings' (RNS) covers general regulatory milestones. Since it is a press release detailing regulatory achievements leading to clinical trials, RNS is the most encompassing fallback for non-financial, non-governance specific corporate news. I will classify it as RNS as it is a formal announcement of regulatory achievement enabling clinical trials.
2010-09-22 English
AB SCIENCE - Conversion des actions de préférence
AGM Information Classification · 99% confidence The document text explicitly mentions "Assemblée générale des actionnaires" (Shareholders' General Meeting) and details decisions made during this meeting, specifically the conversion of preference shares into ordinary shares and the subsequent admission to trading of these new ordinary shares. This content directly relates to the proceedings and outcomes of a General Meeting. The most appropriate classification among the provided options is AGM Information (AGM-R), as it details actions taken at the AGM, even though it is not a presentation slide deck, it is material related to the AGM proceedings.
2010-09-10 French
AB SCIENCE - Conversion of preferred shares
AGM Information Classification · 99% confidence The document explicitly discusses a 'General shareholders' meeting' where shareholders voted on a specific corporate action: the 'Conversion of preferred shares into ordinary shares'. This action directly impacts the company's capital structure and share count. While it relates to a general meeting (suggesting AGM-R or DVA), the core subject is the resulting change in the number of shares outstanding due to the conversion. This aligns best with the 'Share Issue/Capital Change' definition (SHA), as the conversion increases the total number of ordinary shares traded. It is not a simple announcement of voting results (DVA) but the outcome leading to a capital structure change.
2010-09-10 English
AB Sciences - Résultats semestriels 2010
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2010 (interim period), titled 'Résultats financiers du premier semestre 2010'. It contains detailed financial statements, including the 'Etat de situation financière' (Balance Sheet) and analysis of the income statement, operating results, and cash flow. It is not a mere announcement or certification, as it provides substantive financial data and management commentary on the company's performance for the period. H1 2010
2010-09-08 French
AB Science - 2010 Half year results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ended June 30, 2010, for AB Science SA. It includes detailed financial statements (consolidated balance sheet, income statement data), management commentary on financial results, business updates, and operational highlights. Since it covers a period shorter than a full fiscal year and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2010
2010-09-08 English
AB Science - Rapport financier semestriel 2010
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Semi-annual Financial Report) for AB Science S.A. as of June 30, 2010. It contains a declaration by the CEO, a management report (Rapport semestriel d'activité), detailed financial statements (IFRS), and analysis of financial results, cash flow, and risks. Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H2 2010
2010-09-08 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.